March 31, 2021
JCR Pharmaceuticals said on March 30 that it has obtained orphan drug designation for JR-171, a blood-brain-barrier (BBB)-penetrating α-L-iduronidase, for the treatment of mucopolysaccharidosis type I (MPS I). MPS I is an autosomal recessive lysosomal storage disease caused by a...read more